Business
NetworkNewsWire Announces Publication Highlighting Unique Technology in Cannabinoid-Based Medicine
New York, New York--(Newsfile Corp. - September 28, 2017) - NetworkNewsWire ("NNW"), a multi...
About this update from Infield Minerals Corp
[{"type":"text","content":"NetworkNewsWire Announces Publication Highlighting Unique Technology in Cannabinoid-Based MedicineNew York, New York--(Newsfile Corp. - September 28, 2017) - NetworkNewsWire (\"NNW\"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.The publication, titled, \"Medical Cannabis Companies Leverage Biosynthesis to Boost Drug Development,\" discusses companies bringing cannabis-based solutions to the medical marijuana market. To view the full publication, visit: https://www.networknewswire.com/medical-cannabis-companies-leverage-biosynthesis-boost-drug-development/ \"For biotech companies looking to harness these compounds for drug development, the challenge is two-pronged: the time consuming, expensive process of sourcing cannabinoids naturally and removing impurities, or safely and efficiently attempting chemical synthesis of compounds identical to those found in nature, a problem driven by the requirements of the FDA. InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile) has found a solution to these problems by utilizing the DNA of naturally occurring cannabinoids to produce, in a laboratory setting, compounds identical to those found in nature. The future of cannabinoid-based medicine hinges on such innovations which is: the ability to produce cannabinoids identical to those found in nature in a safe, consistent and economical fashion to advance cannabis-based drug development.\"Aside from its biosynthesis program, a considerable portion of InMed's potential centers on the fact that it has the world's leading experts to advance and commercialize the technology it has perfected. The recent addition of Ben Paterson, P.E., as a consultant is case-in-point. Paterson previously served as a senior engineering advisor with Eli Lilly and Company, where he spent 24 of his 37 years in their biosynthesis division. His expertise includes defining laboratory process and scaling them to support pilot and commercial scale development, and integrating biochemistry, equipment, and process control. Paterson is also experienced at designing, constructing, operating, optimizing, and troubleshoo...